{"protocolSection": {"identificationModule": {"nctId": "NCT01200407", "orgStudyIdInfo": {"id": "B1581001"}, "organization": {"fullName": "Pfizer", "class": "INDUSTRY"}, "briefTitle": "Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients", "officialTitle": "AN OPEN LABEL, NON-INTERVENTIONAL STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF AMLODIPINE AND OLMESARTAN MEDOXOMIL (NORMETECTM) IN FILIPINO PATIENTS WITH HYPERTENSION: A POST MARKETING SURVEILLANCE STUDY"}, "statusModule": {"statusVerifiedDate": "2021-07", "overallStatus": "TERMINATED", "whyStopped": "The requirement for Post Marketing Surveillance was lifted by the Philippine FDA", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-06-09", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2014-01-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-01-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-08-25", "studyFirstSubmitQcDate": "2010-09-10", "studyFirstPostDateStruct": {"date": "2010-09-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-06-12", "resultsFirstSubmitQcDate": "2021-07-26", "resultsFirstPostDateStruct": {"date": "2021-08-17", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-07-26", "lastUpdatePostDateStruct": {"date": "2021-08-17", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Pfizer", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine the safety, tolerability and efficacy of Amlodipine and Olmesartan medoxomil among Hypertensive Filipino patients."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension", "fixed drug combination", "Filipinos", "Amlodipine", "Olmesartan medoxomil", "uncontrolled hypertension", "difficult to treat hypertension"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "OTHER", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 615, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Filipino Hypertensive patients", "description": "Male and Female, 18 to 65 year old Filipino hypertensive patients prescribed by their doctors with Normetec", "interventionNames": ["Drug: Amlodipine + Olmesartan medoxomil"]}], "interventions": [{"type": "DRUG", "name": "Amlodipine + Olmesartan medoxomil", "description": "start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up", "armGroupLabels": ["Filipino Hypertensive patients"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)", "description": "An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last study drug administration (Week 12) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.", "timeFrame": "Baseline up to 28 days after last study drug administration (Week 12)"}, {"measure": "Change From Baseline in SBP and DBP at Week 12 With Last Observation Carried Forward (LOCF)", "timeFrame": "Baseline, Week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 4, 8 and 12 Without (w/o) LOCF", "timeFrame": "Baseline, Week 4, Week 8, Week 12"}, {"measure": "Percentage of Participants Achieving JNC VII Recommended Blood Pressure Goal at Week 12 With LOCF", "description": "Based on JNC VII, the ultimate public health goal of antihypertensive therapy is to reduce cardiovascular and renal morbidity and mortality. The JNC VII recommended BP goal is \\<140/90 mmHg and \\<130/80 mmHg for participants with diabetes.", "timeFrame": "Baseline, Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Filipino hypertensive subjects ages 18-65 years old whether naive or currently taking any other anti-hypertensive or those on monotherapy using CCBs or ARBs whom they want to shift on a fixed dose combination drug\n\nExclusion Criteria:\n\n* Patients with contraindications to any of the component of the fixed drug (amlodipine or olmesartan medoxomil) or with malignant or secondary hypertension", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Filipino Hypertensive patients ages 18-65 years old", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Pfizer CT.gov Call Center", "affiliation": "Pfizer", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Lorma Medical Center", "city": "San Fernando City", "state": "LA Union", "zip": "2500", "country": "Philippines"}, {"facility": "Holy Child Hospital", "city": "Taclobo, Dumaguete City", "state": "Negros Oriental", "country": "Philippines"}, {"facility": "Private Clinic", "city": "Albay", "country": "Philippines"}, {"facility": "Private Clinic", "city": "Angono", "country": "Philippines", "geoPoint": {"lat": 14.5266, "lon": 121.1536}}, {"facility": "Private Clinic", "city": "Baguio City", "country": "Philippines", "geoPoint": {"lat": 16.41639, "lon": 120.59306}}, {"facility": "Pines City Doctors Hospital", "city": "Baguio", "country": "Philippines", "geoPoint": {"lat": 16.41639, "lon": 120.59306}}, {"facility": "Private Clinic", "city": "Bulacan", "country": "Philippines", "geoPoint": {"lat": 14.79278, "lon": 120.87889}}, {"facility": "Private Clinic", "city": "Calamba", "country": "Philippines", "geoPoint": {"lat": 14.21167, "lon": 121.16528}}, {"facility": "Private Clinic", "city": "Cavite", "country": "Philippines", "geoPoint": {"lat": 15.67785, "lon": 120.76978}}, {"facility": "Private Clinic", "city": "Cebu City", "country": "Philippines", "geoPoint": {"lat": 10.31672, "lon": 123.89071}}, {"facility": "Private Clinic", "city": "Cebu", "country": "Philippines", "geoPoint": {"lat": 10.31672, "lon": 123.89071}}, {"facility": "Private Clinic", "city": "Dagupan", "country": "Philippines", "geoPoint": {"lat": 16.04313, "lon": 120.33325}}, {"facility": "Private Clinic", "city": "Davao City", "country": "Philippines", "geoPoint": {"lat": 7.07306, "lon": 125.61278}}, {"facility": "Private Clinic", "city": "Davao", "country": "Philippines", "geoPoint": {"lat": 7.07306, "lon": 125.61278}}, {"facility": "Private Clinic", "city": "Eastwood", "country": "Philippines"}, {"facility": "Private Clinic", "city": "Iloilo City", "country": "Philippines", "geoPoint": {"lat": 10.69694, "lon": 122.56444}}, {"facility": "Private Clinic", "city": "Iloilo", "country": "Philippines", "geoPoint": {"lat": 10.69694, "lon": 122.56444}}, {"facility": "Private Clinic", "city": "Isabela", "country": "Philippines", "geoPoint": {"lat": 6.70407, "lon": 121.97117}}, {"facility": "Private Clinic", "city": "Kalibo Aklan", "country": "Philippines"}, {"facility": "Private Clinic", "city": "Laguna", "country": "Philippines"}, {"facility": "Private Clinic", "city": "Laoag", "country": "Philippines", "geoPoint": {"lat": 18.1978, "lon": 120.5957}}, {"facility": "Jesus Nazarene General Hospital", "city": "Lingayen, Pangasinan", "country": "Philippines"}, {"facility": "Makati Medical Center", "city": "Makati City", "country": "Philippines", "geoPoint": {"lat": 14.55027, "lon": 121.03269}}, {"facility": "Private Clinic", "city": "Makati City", "country": "Philippines", "geoPoint": {"lat": 14.55027, "lon": 121.03269}}, {"facility": "Private Clinic", "city": "Makati", "country": "Philippines", "geoPoint": {"lat": 14.55027, "lon": 121.03269}}, {"facility": "Private Clinic", "city": "Mandaluyong", "country": "Philippines", "geoPoint": {"lat": 14.27028, "lon": 120.91457}}, {"facility": "Healthway Medical Clinic", "city": "Manila", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Isaac and Catalina Medical Center", "city": "Manila", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Metropolitan Medical Center Institutional Review Board", "city": "Manila", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Metropolitan Medical Center", "city": "Manila", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Private Clinic", "city": "Manila", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "The Medical City", "city": "Manila", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Private Clinic", "city": "Marikina City", "country": "Philippines", "geoPoint": {"lat": 14.6481, "lon": 121.1133}}, {"facility": "Private Clinic", "city": "Marikina", "country": "Philippines"}, {"facility": "Private Clinic", "city": "Metro Manila", "country": "Philippines"}, {"facility": "Private Clinic", "city": "Muntinlupa", "country": "Philippines", "geoPoint": {"lat": 14.34605, "lon": 121.05555}}, {"facility": "Private Clinic", "city": "Nueva Vizcaya", "country": "Philippines"}, {"facility": "Private Clinic", "city": "Olongapo", "country": "Philippines", "geoPoint": {"lat": 14.82917, "lon": 120.28278}}, {"facility": "Private Clinic", "city": "Pampanga", "country": "Philippines", "geoPoint": {"lat": 7.11, "lon": 125.64889}}, {"facility": "Private Clinic", "city": "Paranaque", "country": "Philippines"}, {"facility": "Private Clinic", "city": "Para\u00f1aque", "country": "Philippines"}, {"facility": "Private Clinic", "city": "Pasay", "country": "Philippines", "geoPoint": {"lat": 14.53748, "lon": 121.00144}}, {"facility": "Private Clinic", "city": "Pasig City", "country": "Philippines", "geoPoint": {"lat": 14.58691, "lon": 121.0614}}, {"facility": "Dr. Agnes Vargas", "city": "Pasig Ciy", "country": "Philippines"}, {"facility": "Private cCinic", "city": "Pasig", "country": "Philippines", "geoPoint": {"lat": 14.58691, "lon": 121.0614}}, {"facility": "Private Clinic", "city": "Pasig", "country": "Philippines", "geoPoint": {"lat": 14.58691, "lon": 121.0614}}, {"facility": "Private Clinic", "city": "Puerto Princesa", "country": "Philippines", "geoPoint": {"lat": 9.73917, "lon": 118.73528}}, {"facility": "Armed Forces of the Philippines Medical Center", "city": "Quezon City", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Private Clinic", "city": "Quezon City", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Angono Medics", "city": "Rizal", "country": "Philippines", "geoPoint": {"lat": 15.7118, "lon": 121.1061}}, {"facility": "Private Clinic", "city": "San Juan", "country": "Philippines", "geoPoint": {"lat": 14.6, "lon": 121.0333}}, {"facility": "Private Clinic", "city": "Tacloban", "country": "Philippines", "geoPoint": {"lat": 11.24333, "lon": 125.00472}}, {"facility": "Private Clinic", "city": "Taguig", "country": "Philippines", "geoPoint": {"lat": 14.52429, "lon": 121.07921}}, {"facility": "Private Clinic", "city": "Tarlac", "country": "Philippines"}, {"facility": "Private Clinic", "city": "Tugegarao", "country": "Philippines"}, {"facility": "Priavte Clinic", "city": "Tuguegarao City", "country": "Philippines", "geoPoint": {"lat": 17.61577, "lon": 121.72285}}, {"facility": "Private Clinic", "city": "Tuguegarao City", "country": "Philippines", "geoPoint": {"lat": 17.61577, "lon": 121.72285}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "To obtain contact information for a study center near you, click here.", "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1581001&StudyName=Amlodipine%20And%20Olmesartan%20Medoxomil%20In%20Hypertensive%20Filipino%20Patients"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The diagnostic criteria of hypertension (defined by Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure \\[JNC VII\\] as systolic blood pressure \\[BP\\] \\>=140 mmHg and diastolic BP \\>=90 mmHg) and the dosage of study medication were consistent with the investigator's routine clinical setting.", "groups": [{"id": "FG000", "title": "Normetec", "description": "Amlodipine/olmesartan medoxomil(Normetec) was prescribed and administered at the recommended starting dose of 5/20 milligrams (mg) once daily according to approved product information in the Philippines."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "615"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "533"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "82"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "56"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "19"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The full analysis set included all subjects who received at atleast 1 dose of amlodipine and olmesartan medoxomil.", "groups": [{"id": "BG000", "title": "Normetec", "description": "Amlodipine/olmesartan medoxomil(Normetec) was prescribed and administered at the recommended starting dose of 5/20 milligrams (mg) once daily according to approved product information in the Philippines."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "613"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.7", "spread": "11.0"}]}]}]}, {"title": "Sex/Gender, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "334"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "277"}]}, {"title": "Unspecified", "measurements": [{"groupId": "BG000", "value": "2"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Asian", "measurements": [{"groupId": "BG000", "value": "610"}]}, {"title": "Unspecified", "measurements": [{"groupId": "BG000", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)", "description": "An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last study drug administration (Week 12) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.", "populationDescription": "The safety analysis population included all participants who received at least 1 dose of study medication during the observation period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline up to 28 days after last study drug administration (Week 12)", "groups": [{"id": "OG000", "title": "Normetec", "description": "Amlodipine/olmesartan medoxomil(Normetec) was prescribed and administered at the recommended starting dose of 5/20 milligrams (mg) once daily according to approved product information in the Philippines."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "613"}]}], "classes": [{"title": "Number of Participants with AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}]}]}, {"title": "Number of Participants with SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in SBP and DBP at Week 12 With Last Observation Carried Forward (LOCF)", "populationDescription": "The full analysis population included all participants who received at least 1 dose of study medication during the observation period; number analyzed=number of participants with observed value in category. LOCF method was used to impute missing values.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "millimeters of mercury (mmHg)", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Normetec", "description": "Amlodipine/olmesartan medoxomil(Normetec) was prescribed and administered at the recommended starting dose of 5/20 milligrams (mg) once daily according to approved product information in the Philippines."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "613"}]}], "classes": [{"title": "Baseline: SBP", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "575"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "161.6", "spread": "16.04"}]}]}, {"title": "Baseline: DBP", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "575"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "98.9", "spread": "9.33"}]}]}, {"title": "Change at Week 12: SBP LOCF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "574"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-35.8", "spread": "16.74"}]}]}, {"title": "Change at Week12: DBP LOCF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "574"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.4", "spread": "10.39"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "SBP with LOCF (Week 12)", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.000", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-35.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-37.2", "ciUpperLimit": "-34.4"}, {"groupIds": ["OG000"], "groupDescription": "DBP with LOCF (Week 12)", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.000", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-19.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.3", "ciUpperLimit": "-18.6"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 4, 8 and 12 Without (w/o) LOCF", "populationDescription": "The full analysis population included all participants who received at least 1 dose of study medication during the observation period; number analyzed=number of participants with observed value in category.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Baseline, Week 4, Week 8, Week 12", "groups": [{"id": "OG000", "title": "Normetec", "description": "Amlodipine/olmesartan medoxomil(Normetec) was prescribed and administered at the recommended starting dose of 5/20 milligrams (mg) once daily according to approved product information in the Philippines."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "613"}]}], "classes": [{"title": "Change at Week 4: SBP w/o LOCF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "551"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-24.7", "spread": "16.33"}]}]}, {"title": "Change at Week 4: DBP w/o LOCF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "551"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-13.2", "spread": "9.46"}]}]}, {"title": "Change and Week 8: SBP w/o LOCF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "506"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-33.0", "spread": "16.36"}]}]}, {"title": "Change and Week 8: DBP w/o LOCF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "506"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-17.6", "spread": "9.99"}]}]}, {"title": "Change and Week 12: SBP w/o LOCF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "423"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-36.3", "spread": "16.64"}]}]}, {"title": "Change and Week 12: DBP w/o LOCF", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "423"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-19.9", "spread": "9.99"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "SBP w/o LOCF (Week 4)", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.000", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-24.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-26.1", "ciUpperLimit": "-23.4"}, {"groupIds": ["OG000"], "groupDescription": "SBP w/o LOCF (Week 8)", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.000", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-33.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-34.4", "ciUpperLimit": "-31.6"}, {"groupIds": ["OG000"], "groupDescription": "SBP w/o LOCF (Week 12)", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.000", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-36.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-37.9", "ciUpperLimit": "-34.7"}, {"groupIds": ["OG000"], "groupDescription": "DBP w/o LOCF (Week 4)", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.000", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-13.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.0", "ciUpperLimit": "-12.4"}, {"groupIds": ["OG000"], "groupDescription": "DBP w/o LOCF (Week 8)", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.000", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-17.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-18.4", "ciUpperLimit": "-16.7"}, {"groupIds": ["OG000"], "groupDescription": "DBP w/o LOCF (Week 12)", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.000", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-19.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.8", "ciUpperLimit": "-18.9"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving JNC VII Recommended Blood Pressure Goal at Week 12 With LOCF", "description": "Based on JNC VII, the ultimate public health goal of antihypertensive therapy is to reduce cardiovascular and renal morbidity and mortality. The JNC VII recommended BP goal is \\<140/90 mmHg and \\<130/80 mmHg for participants with diabetes.", "populationDescription": "The full analysis population included all participants who received at least 1 dose of study medication during the observation period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Normetec", "description": "Amlodipine/olmesartan medoxomil(Normetec) was prescribed and administered at the recommended starting dose of 5/20 milligrams (mg) once daily according to approved product information in the Philippines."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "613"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "70.5", "lowerLimit": "66.9", "upperLimit": "74.1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Baseline up to 28 days after last study drug administration (Week 12)", "eventGroups": [{"id": "EG000", "title": "Normetec", "description": "Amlodipine/olmesartan medoxomil(Normetec) was prescribed and administered at the recommended starting dose of 5/20 milligrams (mg) once daily according to approved product information in the Philippines.", "seriousNumAffected": 0, "seriousNumAtRisk": 613, "otherNumAffected": 6, "otherNumAtRisk": 613}], "otherEvents": [{"term": "Vertigo positional", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 613}]}, {"term": "Chest Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 613}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 613}]}, {"term": "Drug hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 613}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 613}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 613}]}, {"term": "Pruritus", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 18.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 613}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "This was an observational, non-interventional study which evaluated Filipino patients with hypertension at the outpatient clinic, and as such, study medication was prescribed at the discretion of the attending physician."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single enter publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."}, "pointOfContact": {"title": "Pfizer ClinicalTrials.gov Call Center", "organization": "Pfizer, Inc.", "email": "ClinicalTrials.gov_Inquiries@pfizer.com", "phone": "1-800-718-1021"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "C000437965", "term": "Olmesartan"}, {"id": "D000068557", "term": "Olmesartan Medoxomil"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M91890", "name": "Olmesartan", "asFound": "Anticoagulation", "relevance": "HIGH"}, {"id": "M273", "name": "Olmesartan Medoxomil", "asFound": "Sleep hygiene", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}